Online first
Opis przypadku
Opublikowany online: 2024-09-24
Wyświetlenia strony
104
Wyświetlenia/pobrania artykułu
88
Kaptopril – nie zawsze krótkodziałający inhibitor konwertazy angiotensyny
DOI: 10.5603/fc.101861
Streszczenie
-
Słowa kluczowe: kaptoprilinhibitory konwertazy angiotensyny (ACEi)obrzęk naczynio-ruchowy
Referencje
- Montinaro V, Cicardi M. ACE inhibitor-mediated angioedema. Int Immunopharmacol. 2020; 78.
- Erickson DL, Coop CA. Angiotensin-converting enzyme inhibitor-associated angioedema treated with c1-esterase inhibitor: A case report and review of the literature. Allergy Rhinol (Providence). 2016; 7(3): 168–171.
- Kostis WJ, Shetty M, Chowdhury YS, et al. ACE inhibitor-induced angioedema: a review. Curr Hypertens Rep. 2018; 20(7): 55.
- Patel G, Pongracic JA. Hereditary and acquired angioedema. Allergy Asthma Proc. 2019; 40(6): 441–445.
- Prematta MJ, Prematta T, Craig TJ. Treatment of hereditary angioedema with plasma-derived C1 inhibitor. Ther Clin Risk Manag. 2008; 4(5): 975–982.
- Rasmussen E, Bindslev-Jensen C, Bygum A. Angioødem – udredning og behandling. Tidsskrift for Den norske legeforening. 2012; 132(21): 2391–2395.
- Chaaya G, Afridi F, Faiz A, et al. When nothing else works: fresh frozen plasma in the treatment of progressive, refractory angiotensin-converting enzyme inhibitor-induced angioedema. Cureus. 2017; 9(1): e972.
